A5012114658- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- Immunodeficiency and Autoimmune Disorders
- Glycosylation and Glycoproteins Research
- Monoclonal and Polyclonal Antibodies Research
- PI3K/AKT/mTOR signaling in cancer
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Galectins and Cancer Biology
- Advanced Breast Cancer Therapies
- Phagocytosis and Immune Regulation
- Calcium signaling and nucleotide metabolism
- Cell Adhesion Molecules Research
- RNA modifications and cancer
- Viral-associated cancers and disorders
- Acute Myeloid Leukemia Research
- Cancer-related Molecular Pathways
- Gastrointestinal Tumor Research and Treatment
- Chronic Myeloid Leukemia Treatments
- Cancer-related molecular mechanisms research
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Renal Diseases and Glomerulopathies
- CAR-T cell therapy research
Centro di Riferimento Oncologico
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2025
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2010-2014
Ospedale Maggiore
2014
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2014
University of Bologna
2004-2010
University of Siena
2010
University of Modena and Reggio Emilia
2010
St. Eugenio Hospital
2006
University of Rome Tor Vergata
2004
Predictors of chronic lymphocytic leukaemia (CLL) transformation to Richter syndrome (RS) are not established and were investigated in 185 consecutive CLL cases. Actuarial incidence RS (n = 17; all diffuse large B-cell lymphomas) at 10 years was 16.2% (95% confidence interval: 8.0-24.4%). At diagnosis, prognosticators by univariate analysis IGHV homology >/=98% (P 0.006), IGHV4-39 usage < 0.001), del13q14 absence 0.004), expression CD38 0.001) ZAP70 size number lymph nodes, advanced Binet...
Although CD49d is an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL), definitive validation evidence lacking. A worldwide multicenter analysis was performed using published and unpublished CLL series to evaluate the impact of as overall (OS) treatment-free survival (TFS) predictor.A training/validation strategy chosen find optimal cutoff. The hazard ratio (HR) for death treatment imposed by estimated pooled 2,972 CLLs; Cox stratified center stage used adjust confounding...
CD38 and CD49d are associated negative prognosticators in chronic lymphocytic leukemia (CLL). Despite evidence that both molecules involved interactions occurring between CLL normal cells the context of CLL-involved tissues, a functional link is still missing. Using gene expression profiles comparing CD38(+)CD49d(+) versus CD38(-)CD49d(-) cells, we showed overexpression CCL3 CCL4 chemokines from former group. These were also up-regulated by signals CLL; moreover, was expressed bone marrow...
Abstract Purpose: Activation of the PI3K/mTOR signaling pathway is recurrent in different lymphoma types, and pharmacologic inhibition has shown activity patients. Here, we extensively characterized vitro vivo mechanism action PQR309 (bimiralisib), a novel oral selective dual inhibitor under clinical evaluation, preclinical models. Experimental Design: This study included screening on large panel cell lines, both as single agent combination, validation experiments models primary cells,...
The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B cell receptor (BCR) signals, demonstrates remarkable clinical activity in chronic lymphocytic leukemia (CLL). lymphocytosis experienced by most patients under ibrutinib has previously been attributed to inhibition of BTK-dependent integrin and chemokine cues operating retain the tumor cells nodal compartments. Here, we show that VLA-4 integrin, as expressed CD49d-positive CLL, can be inside-out activated upon BCR...
Abstract Loss-of-function mutations in NFKBIE, which encodes for the NF-κB inhibitor IκBε, are frequent chronic lymphocytic leukemia (CLL) and certain other B-cell malignancies have been associated with accelerated disease progression inferior responses to chemotherapy. Using vitro vivo murine models primary patient samples, we now show that NFKBIE-mutated CLL cells selected by microenvironmental signals activate pathway induce alterations within tumor microenvironment can allow immune...
The balanced activity of microtubule-stabilizing and -destabilizing proteins determines the extent microtubule dynamics, which is implicated in many cellular processes, including adhesion, migration, morphology. Among destabilizing proteins, stathmin overexpressed different human malignancies has been recently linked to regulation cell motility. observation that was recurrent metastatic sarcomas prompted us investigate contribution tumor local invasiveness distant dissemination. We found...
A fraction of chronic lymphocytic leukaemia (CLL) cases carry highly homologous B-cell receptors (BCR), i.e. characterized by non-random combinations immunoglobulin heavy-chain variable (IGHV) genes and complementarity determining region-3 (HCDR3), often associated with a restricted selection IGVK/L light chains. Such 'stereotyped' BCR occur more frequently in CLL unmutated (UM) than mutated (M) IGHV genes. We analysed 1426 IG rearrangements (from 1398 cases) clustering driven HCDR3...
Significance CLL is characterized by autonomous B cell receptor (BCR) signaling. subsets are empirically defined sequence similarities of the BCR heavy chain. However, in unfavorable subset 2, an acquired mutation (termed R110) light chain stimulates This study demonstrates that oncogenic R110 dictates prognosis and not restricted to conventional 2. Interestingly, carriers a particular light-chain allele ( IGLV3-21 * 01 ) predisposed develop because this enables signaling as single-point...
Abstract Cancer heterogeneity at the proteome level may explain differences in therapy response and prognosis beyond currently established genomic transcriptomic-based diagnostics. The relevance of proteomics for disease classifications remains to be clinically heterogeneous cancer entities such as chronic lymphocytic leukemia (CLL). Here, we characterize transcriptome alongside genetic ex-vivo drug profiling a annotated CLL discovery cohort (n = 68). Unsupervised clustering data reveals six...
In chronic lymphocytic leukemia the balance between pro-apoptotic and anti-apoptotic members of bcl-2 family is involved in pathogenesis, chemorefractoriness clinical outcome. Moreover, recently proposed anti-bcl-2 molecules, such as ABT-199, have emphasized potential role proteins context target therapies. We investigated bax/bcl-2 ratio by flow cytometry 502 patients identified a cut off 1.50 to correlate with well-established biological prognosticators. Bax/bcl-2 was or over 263 (52%)...
Multiple Myeloma (MM) is a neoplastic disorder characterized by clonal proliferation of malignant plasma cells (PCs). Flow cytometry an essential tool to confirm diagnosis and evaluate minimal residual disease (MRD). This study aims at identifying new surface PC markers suitable for targeted therapy in MM able improve MRD detection.The expression 82 molecules provided the "Ninth International Workshop on Leukocyte Antigens" was analyzed flow 5 cell lines 20 newly diagnosed (NDMM) patients....
Abstract Purpose: In chronic lymphocytic leukemia (CLL), TP53 mutations are associated with reduced survival and resistance to standard chemoimmunotherapy (CIT). Nevertheless, the clinical impact of subclonal below 10% 15% variant allele frequency (VAF) remains unclear. Experimental Design: Using a training/validation approach, we retrospectively analyzed biological features above (high-VAF) or (low-VAF) previously reported 10.0% VAF threshold, as determined by deep next-generation...
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib represents an effective strategy for treatment of chronic lymphocytic leukemia (CLL), nevertheless about 30% patients eventually undergo disease progression. Here we investigated by flow cytometry the long-term modulation CLL CXCR4
Circulating tumor DNA (ctDNA) levels can help predict outcomes in diffuse large B-cell lymphoma (DLBCL), but its integration with DLBCL molecular clusters remains unexplored. Using the LymphGen tool 77 both ctDNA and tissue biopsy, a 95.8% concordance rate cluster assignment was observed, showing reproducibility of clustering on ctDNA. A multicenter, prospective cohort 166 newly diagnosed analyzed for using CAPP-seq. Patients &lt; 2.5 log10hGE/mL had 4-year progression-free survival...